Drug sensitivity in cancer cell lines is not tissue-specific

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Jaeger, Samira ^a   Duran Frigola, Miquel ^a   Aloy, Patrick ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Cancer cell lines; Drug sensitivity; Tissue specificity

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ERLOTINIB; FIGITUMUMAB; FULVESTRANT; GEFITINIB; LETROZOLE; MIDOSTAURIN; PALBOCICLIB; RALOXIFENE; TAMOXIFEN; VANDETANIB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER TISSUE; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; PROSTATE CANCER; SYSTEMS BIOLOGY; TISSUE SPECIFICITY; TUMOR MICROENVIRONMENT; ANTIBODY SPECIFICITY; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ORGAN SPECIFICITY;

EID: 84928728829     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0312-6     Document Type: Article

References (20)

1. Weinstein JN. Drug discovery: cell lines battle cancer. Nature. 2012;483:544-5.
2. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570-5.
3. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-3.
4. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010;102:1310-21.
5. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813-23.
6. Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010;68:309-18.
7. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105:452-8.
8. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.
9. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377-84.
10. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 1805;2010:105-17.
11. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7:659-72.
12. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
13. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
14. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
15. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603-7.
16. Moghaddas Gholami A, Hahne H, Wu Z, Auer FJ, Meng C, Wilhelm M, et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 2013;4:609-20.
17. Ferreira D, Adega F, Chaves R. The Importance of Cancer Cell lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing. In: Lopez-Camarillo C, Arechaga-Ocampo E, editors. Oncogenomics and Cancer Proteomics -Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer. InTech. 2013.
18. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013;73:4372-82.
19. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-35.
20. Dancik GM, Ru Y, Owens CR, Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res. 2011;71:7398-409.